BACKGROUND/AIMS: Quinolinic acid is an endogenous neuroexcitant derived from tryptophan. Brain quinolinic acid concentrations are reportedly elevated in chronic liver failure. The aim of this study was to determine if brain quinolinic acid levels correlate with the severity of hepatic encephalopathy. METHODS: Postmortem samples of selected brain regions and plasma samples taken at several stages of encephalopathy were obtained from patients with acute and chronic liver failure. Quinolinic acid levels were measured by mass spectroscopy using [18O]quinolinic acid. RESULTS: Plasma quinolinic acid levels were significantly increased by stage I encephalopathy in patients with acute liver failure and by stages II and III in patients with chronic liver failure. Brain quinolinic acid levels were elevated only in patients with acute liver failure and were uniformly distributed at concentrations below those observed in plasma. CONCLUSIONS: The uniform distribution of quinolinic acid at subplasma concentrations in the brains of patients with acute liver failure suggests that it is synthesized peripherally and enters the brain across a permeabilized blood-brain barrier. Whereas the elevation of brain quinolinic acid levels in patients who died of acute but not chronic liver failure suggests that the involvement of quinolinic acid in the pathogenesis of hepatic encephalopathy is minimal, it could predispose these patients to seizures.
BACKGROUND/AIMS: Quinolinic acid is an endogenous neuroexcitant derived from tryptophan. Brain quinolinic acid concentrations are reportedly elevated in chronic liver failure. The aim of this study was to determine if brain quinolinic acid levels correlate with the severity of hepatic encephalopathy. METHODS: Postmortem samples of selected brain regions and plasma samples taken at several stages of encephalopathy were obtained from patients with acute and chronic liver failure. Quinolinic acid levels were measured by mass spectroscopy using [18O]quinolinic acid. RESULTS: Plasma quinolinic acid levels were significantly increased by stage I encephalopathy in patients with acute liver failure and by stages II and III in patients with chronic liver failure. Brain quinolinic acid levels were elevated only in patients with acute liver failure and were uniformly distributed at concentrations below those observed in plasma. CONCLUSIONS: The uniform distribution of quinolinic acid at subplasma concentrations in the brains of patients with acute liver failure suggests that it is synthesized peripherally and enters the brain across a permeabilized blood-brain barrier. Whereas the elevation of brain quinolinic acid levels in patients who died of acute but not chronic liver failure suggests that the involvement of quinolinic acid in the pathogenesis of hepatic encephalopathy is minimal, it could predispose these patients to seizures.
Authors: Ludwig Kramer; Edith Bauer; Peter Schenk; Rudolf Steininger; Marion Vigl; Reinhold Mallek Journal: Wien Klin Wochenschr Date: 2003-09-15 Impact factor: 1.704
Authors: Katrien Skorobogatov; Livia De Picker; Robert Verkerk; Violette Coppens; Marion Leboyer; Norbert Müller; Manuel Morrens Journal: Front Immunol Date: 2021-09-23 Impact factor: 7.561
Authors: Ezio Bettini; Sara De Martin; Andrea Mattarei; Marco Pappagallo; Stephen M Stahl; Francesco Bifari; Charles E Inturrisi; Franco Folli; Sergio Traversa; Paolo L Manfredi Journal: Pharmaceuticals (Basel) Date: 2022-07-17
Authors: Maria A Tikhonova; Svetlana Y Zhanaeva; Anna A Shvaikovskaya; Nikita M Olkov; Lyubomir I Aftanas; Konstantin V Danilenko Journal: Int J Mol Sci Date: 2022-08-16 Impact factor: 6.208